Abstract | PURPOSE OF REVIEW: The aim of this brief review is to evaluate recent developments in the classification and treatment of eosinophilic myeloid disorders in the context of reactive, lymphocyte-variant, and idiopathic eosinophilias. RECENT FINDINGS: SUMMARY: Molecular/genetic analysis is now mandatory for the diagnosis, classification, and treatment of eosinophilic myeloid disorders. The finding of rearranged, constitutively activated PDGFRA/B identifies patients who are eminently treatable with tyrosine kinase inhibitors.
|
Authors | Jason Gotlib |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 17
Issue 2
Pg. 117-24
(Mar 2010)
ISSN: 1531-7048 [Electronic] United States |
PMID | 20071982
(Publication Type: Journal Article, Review)
|
Chemical References |
- Biomarkers, Tumor
- Protein Kinase Inhibitors
- FGFR1 protein, human
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Platelet-Derived Growth Factor alpha
- Receptor, Platelet-Derived Growth Factor beta
|
Topics |
- Biomarkers, Tumor
(genetics)
- Humans
- Hypereosinophilic Syndrome
(classification, drug therapy, genetics)
- Leukemia, Myeloid
(classification, drug therapy)
- Protein Kinase Inhibitors
(therapeutic use)
- Receptor, Fibroblast Growth Factor, Type 1
(genetics)
- Receptor, Platelet-Derived Growth Factor alpha
(genetics)
- Receptor, Platelet-Derived Growth Factor beta
(genetics)
- World Health Organization
|